


Immunology

Antibodies for Immunology Research

biocell.com



Distributed by




Products are for Research Use Only – Not for therapeutic or diagnostic purposes

www.2BScientific.com

+44 (0)1869 238 033


sales@2BScientific.com

Antibodies for Immunology Research



| Antigen | Reactivity | Application | Clone | Catalog # | Isotype Control |
|-----------------------|-----------------|--|----------------------------|-------------|-----------------|
| 2C TCR | Mouse | IF, FC | 1B2 | BE0069 | BE0083 |
| 4-1BB (CD137) | Mouse | <i>in vivo</i> activation of 4-1BB | LOB12.3 | BP0169 | BP0089 |
| 4-1BB (CD137) | Mouse | <i>in vivo</i> 4-1BB stimulation, <i>in vitro</i> 4-1BB stimulation | 3H3 | BP0239 | BP0089 |
| 4-1BB (CD137) | Mouse | <i>in vitro</i> 4-1BB blockade, FC | 17B5 | BE0296 | BE0087 |
| 4-BBL (CD137L) | Mouse | <i>in vivo</i> 4-BBL blockade, , ELISA | TKS-1 | BE0110 | BE0089 |
| B220 | Mouse | <i>in vivo</i> B cell depletion, <i>in vitro</i> B cell negative selection | RA3.3A1/6.1 | BE0067 | BE0094 |
| B7-1 (CD80) | Mouse | <i>in vivo</i> CD80 blockade, Affinity chromatography | 1G10 | BE0134 | BE0089 |
| BTLA (CD272) | Mouse | <i>in vivo</i> BTLA stimulation, <i>in vivo</i> BTLA blockade | 6A6 | BE0132 | BE0091 |
| BTLA (CD272) | Mouse | <i>in vivo</i> stimulation of BTLA, <i>in vitro</i> stimulation of BTLA, FC | PK18.6 | BE0153 | BE0088 |
| BTLA (CD272) | Mouse | <i>in vivo</i> BTLA blockade, <i>in vitro</i> T cell stimulation/activation, FC | PJ196 | BE0196 | BE0083 |
| BTLA (CD272) | Mouse | <i>in vivo</i> BTLA+ B cell and CD4 T cell depletion, FC | 6F7 | BE0304 | BE0083 |
| c-Kit (CD117) | Mouse | FC, IF, IHC | 2B8 | BE0280 | BE0090 |
| c-Kit (CD117) | Mouse | <i>in vivo</i> mast cell depletion, <i>in vivo</i> c-Kit+ cell depletion, <i>in vitro</i> c-Kit neutralization, IP, FC | ACK2 | BE0293 | BE0090 |
| CCL2 (MCP-1) | Mouse/Human/Rat | <i>in vivo</i> CCL2 neutralization, IHC-F | 2H5 | BE0185 | BE0091 |
| CCR3 (CD193) | Mouse | <i>in vivo</i> eosinophil depletion | 6S2-19-4 | BE0316 | BE0090 |
| CD1a | Human | <i>in vitro</i> CD1a blockade, FC | OKT-6 | BE0211 | BE0083 |
| CD1d (CD1.1) | Mouse | <i>in vivo</i> CD1d neutralization, , <i>in vitro</i> CD1d neutralization | 19G11 | BE0000 | BE0088 |
| CD1d (CD1.1) | Mouse | iNKT cell neutralization, <i>in vivo</i> CD1d blockade, FC | 20H2 (HB323) | BE0179 | BE0088 |
| CD3 | Human | <i>in vivo</i> T cell depletion in humanized mice, <i>in vitro</i> T cell stimulation/activation, ex vivo T cell inhibition for xenographs, FC | OKT-3 | BE0001-2 | BE0085 |
| CD3 | Mouse | <i>in vitro</i> T cell stimulation/activation | 17A2 | BE0002 | BE0090 |
| CD3 | Human | <i>in vivo</i> T cell depletion in humanized mice, ex vivo T cell inhibition for xenographs, FC | UCHT1 (Leu-4) (T3) | BE0231 | BE0083 |
| CD3ε | Mouse | <i>in vivo</i> T cell depletion, <i>in vitro</i> T cell stimulation/activation, IF, FC, WB | 145-2C11 | BP0001-1 | BP0091 |
| CD3ε | Mouse | <i>in vitro</i> T cell negative selection, <i>in vitro</i> T cell stimulation/activation, IF | KT3 | BE0261 | BE0089 |
| CD3ε F(ab')2 fragment | Mouse | <i>in vivo</i> T cell depletion | 145-2C11 f(ab')2 Fragments | BE0001-1FAB | BE0091-FAB |
| CD4 | Mouse | <i>in vivo</i> CD4+ T cell depletion, FC, WB | GK1.5 | BP0003-1 | BP0090 |
| CD4 | Human | <i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> CD4+ T cell depletion in humanized mice, FC, IP | OKT-4 | BE0003-2 | BE0086 |
| CD4 | Mouse | <i>in vivo</i> blockade of CD4+ T-cell responses, WB | YTS 177 | BE0003-3 | BE0089 |
| CD4 | Mouse | <i>in vivo</i> CD4+ T cell depletion | YTS 191 | BE0119 | BE0090 |
| CD4 | Human | <i>in vitro</i> CD4 blockade, <i>in vitro</i> blocking of CD4+ T cell activation, IF, IHC-F, FC | RPA-T4 | BE0288 | BE0083 |
| CD4 | Rat | <i>in vivo</i> CD4+ T cell depletion, FC | OX-38 | BE0308 | BE0085 |
| CD8 (Lyt 2.1) | Mouse | <i>in vivo</i> CD8+ T cell depletion, FC | 116-13.1 (HB129) | BE0118 | BE0085 |
| CD8α | Mouse | <i>in vivo</i> CD8+ T cell depletion, IF, FC, WB | 53-6.7 | BP0004-1 | BP0089 |
| CD8α | Human | <i>in vivo</i> CD8+ T cell depletion in humanized mice | OKT-8 | BE0004-2 | BE0085 |
| CD8α | Mouse | <i>in vivo</i> CD8+ T cell depletion, WB | 2.43 | BP0061 | BP0090 |
| CD8α | Mouse | <i>in vivo</i> CD8+ T cell depletion, WB | YTS 169.4 | BE0117 | BP0090 |
| CD8β (Lyt 3.2) | Mouse | <i>in vivo</i> CD8+ T cell depletion, <i>in vitro</i> CD8 blockade, IF | 53-5.8 | BE0223 | BE0088 |
| CD11b | Mouse/Human | <i>in vivo</i> CD11b neutralization, ILC2 cell purification, FC | M1/70 | BE0007 | BE0090 |
| CD16/CD32 | Mouse | <i>in vitro</i> Fc receptor blocking, <i>in vivo</i> Fc receptor blocking | 2.4G2 | BE0307 | BE0090 |
| CD19 | Mouse | <i>in vivo</i> B cell depletion, <i>in vivo</i> CD19 neutralization, <i>in vitro</i> B cell negative selection, FC | 1D3 | BE0150 | BE0089 |
| CD19 | Human | FC, Functional assays, IF, Chimeric antigen receptor construction | 4G7 | BE0281 | BE0083 |
| CD20 | Mouse | <i>in vivo</i> B cell depletion, WB | MB20-11 | BP0356 | BP0366 |
| CD22 | Mouse | <i>in vivo</i> B cell depletion in combination with anti-CD19 (clone 1D3) and anti-rat x Light Chain (clone MAR 18.5), FC, IP | Cy34.1 | BE0011 | BE0083 |
| CD24 | Mouse | <i>in vivo</i> administration, IHC-F, IHC-P, IF, FC | M1/69 | BE0360 | BE0090 |
| CD25 (IL-2Rα) | Mouse | <i>in vivo</i> regulatory T cell depletion, FC | PC-61.5.3 | BP0012 | BP0088 |
| CD25 (IL-2Rα) | Human | <i>in vivo</i> regulatory T cell depletion in humanized mice, IP, IF | 7G7B6 | BE0014 | BE0085 |
| CD27 | Mouse | <i>in vivo</i> CD27 stimulation, <i>in vitro</i> CD27 stimulation, IP, FC | RM27-3E5 | BE0348 | BE0089 |
| CD28 | Mouse | <i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> CD28 blockade | 37.51 | BE0015-1 | BE0087 |
| CD28 | Mouse | <i>in vitro</i> T cell stimulation/activation | PV-1 | BE0015-5 | BE0091 |
| CD28 | Mouse | <i>in vivo</i> T cell stimulation/activation, <i>in vitro</i> T cell stimulation/activation | D665 | BE0328 | BE0083 |
| CD32 (FcγRIIA) | Human | <i>in vivo</i> Fc _γ RIIA blockade in humanized mice, <i>in vitro</i> Fc _γ RIIA blockade, ELISA, FC | IV.3 | BE0224 | BE0086 |
| CD38 | Mouse | <i>in vivo</i> CD38 stimulation, <i>in vitro</i> CD38 stimulation, <i>in vitro</i> B cell activation, IF, ELISA, FC | NIMR5 | BE0317 | BE0089 |
| CD40 | Mouse | <i>in vivo</i> CD40 activation, <i>in vitro</i> B cell stimulation/activation | FGK4.5/FGK45 | BP0016-2 | BP0089 |
| CD40 | Human | <i>in vitro</i> CD40 stimulation, Functional assays, FC | G28.5 | BE0189 | BE0083 |


IF Immunofluorescence | IHC-F Immunohistochemistry (frozen) | IHC-P Immunohistochemistry (paraffin) | WB Western blot | IP



| Antigen | Reactivity | Application | Clone | Catalog # | Isotype Control |
|-------------------------------|-----------------|---|---------------------|-----------|-----------------|
| CD40L (CD154) | Mouse | <i>in vivo</i> blocking of CD40/CD40L signaling, <i>in vitro</i> blocking of CD40/CD40L signaling, WB | MR-1 | BP0017-1 | BP0091 |
| CD40L (CD154) | Human/Monkey | <i>in vitro</i> blocking of CD40/CD40L signaling, <i>in vivo</i> blocking of CD40/CD40L signaling, IP, FC | 5C8 | BE0292 | BE0085 |
| CD45RB | Mouse | <i>in vivo</i> anti-CD45RB-mediated tolerance induction, <i>in vivo</i> pre-mNK cell depletion | MB23G2 (HB220) | BE0019 | BE0089 |
| CD45.2 | Mouse | FC, <i>in vivo</i> CD45.2 blockade, <i>in vitro</i> CD45.2 blockade, IHC-F | 104.2 | BE0300 | BE0085 |
| CD47 | Human | <i>in vivo</i> CD47 neutralization in human tumor xenograft models or humanized mice, <i>in vitro</i> CD47 neutralization, FC | B6H12 | BE0019-1 | BE0083 |
| CD47 | Human/Mouse/Rat | <i>in vivo</i> CD47 blockade, <i>in vitro</i> CD47 blocking, IF | MIAP410 | BP0283 | BP0083 |
| CD47 (IAP) | Mouse | <i>in vivo</i> CD47 blockade, <i>in vitro</i> CD47 blockade, IF | MIAP301 | BE0270 | BE0089 |
| CD48 | Mouse | <i>in vivo</i> CD48 blockade, <i>in vitro</i> CD48 blocking | HM48-1 | BE0147 | BE0091 |
| CD54 (ICAM-1) | Mouse | <i>in vivo</i> ICAM-1 neutralization, IHC-F, ELISA | YN1/1.7.4 | BE0020-1 | BE0090 |
| CD69 | Mouse | <i>in vivo</i> down-regulation of CD69 expression, Functional assays | CD69.2.2 | BE0330 | BE0083 |
| CD70 | Mouse | <i>in vivo</i> CD70 blockade, <i>in vitro</i> CD70 blockade, FC | FR70 | BE0022 | BE0090 |
| CD71 (Tfr1) | Mouse | <i>in vivo</i> depletion of CD71+ cells | R17 217.1.3/TIB-219 | BP0175 | BP0089 |
| CD71 (Tfr1) | Mouse | <i>in vivo</i> depletion of CD71+ cells, IF, IHC-F, WB | 8D3 | BP0329 | BP0089 |
| CD71 (Tfr1) | Rat/Mouse | Targeted drug delivery to the brain, IHC-F, FC | OX-26 | BE0331 | BE0085 |
| CD73 | Mouse | <i>in vivo</i> CD73 blockade, <i>in vitro</i> CD73 blockade | TY/23 | BE0209 | BE0089 |
| CD80 (B7-1) | Mouse | <i>in vivo</i> CD80 blockade, FC | 16-10A1 | BE0024 | BE0091 |
| CD86 (B7-2) | Mouse | <i>in vivo</i> CD86 blockade, FC | GL-1 | BE0025 | BE0089 |
| CD96 | Mouse | <i>in vivo</i> CD96 blocking, <i>in vitro</i> CD96 blocking, FC | 3.3 | BE0337 | BE0088 |
| CD103 | Mouse | <i>in vivo</i> CD103 neutralization, IF, FC | M290 | BE0026 | BE0089 |
| CD106 (VCAM-1) | Mouse | <i>in vivo</i> VCAM-1 neutralization, IF | M/K-2.7 | BE0027 | BE0088 |
| CD122 (IL-2R β) | Mouse | <i>in vitro</i> NK cell negative selection, IP, FC | 5H4 | BE0272 | BE0089 |
| CD122 (IL-2R β) | Mouse | <i>in vivo</i> NK cell depletion, <i>in vivo</i> CD122 blockade, <i>in vitro</i> IL-2R blockade, Functional assays, FC | TM-Beta 1 | BE0298 | BE0090 |
| CD132 (common γ chain) | Mouse | <i>in vivo</i> γ c blockade, Functional assays, IP, FC | 3E12 | BE0271 | BE0090 |
| CD172a (SIRP α) | Mouse | <i>in vivo</i> SIRP α blocking, <i>In vitro</i> SIRP α blocking, WB, IP, FC | P84 | BE0322 | BE0088 |
| CD200 (OX2) | Mouse | <i>in vivo</i> CD200 blockade, <i>in vitro</i> CD200 blockade, IHC-F, IF, FC | OX-90 | BE0299 | BE0089 |
| CD209b (SIGN-R1) | Mouse | <i>in vivo</i> SIGN-R1 blockade, IHC-F, WB, FC | 22D1 | BE0220 | BE0091 |
| CD276 (B7-H3) | Mouse | <i>in vivo</i> B7-H3 blockade, FC | MJ18 | BE0124 | BE0088 |
| CD314 (NKG2D) | Mouse | <i>in vivo</i> NKG2D blockade, <i>in vitro</i> NKG2D blockade, FC | CX5 | BE0334 | BE0088 |
| CD317 (BST2, PDCA-1) | Mouse | <i>in vivo</i> pDC depletion, IF, FC | 927 | BE0311 | BE0090 |
| CD326 (EpCAM) | Human | IHC-P, IF, FC, IP | Ber-EP4 | BE0386 | BE0083 |
| CLEC9A (CD370) | Mouse | <i>in vivo</i> CLEC9A blockade, <i>in vivo</i> Ag targeting to CLEC9A+ DCs, WB, ELISA, IP, IF, FC | 7H11 | BE0305 | BE0088 |
| CSF1 | Mouse | <i>in vivo</i> CSF1 neutralization | 5A1 | BE0204 | BE0088 |
| CSF1R (CD115) | Mouse | <i>in vivo</i> macrophage depletion, <i>in vitro</i> CSF1R neutralization, <i>in vivo</i> monocyte depletion, FC, WB | AFS98 | BP0213 | BP0089 |
| CTLA-4 (CD152) | Mouse | <i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, FC, WB | UC10-4F10-11 | BP0032 | BP0091 |
| CTLA-4 (CD152) | Mouse | <i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, WB | 9H10 | BP0131 | BP0087 |
| CTLA-4 (CD152) | Mouse | <i>in vivo</i> CTLA-4 neutralization, WB | 9D9 | BP0164 | BP0086 |
| CTLA-4 (CD152) | Human | <i>in vitro</i> CTLA-4 neutralization, FC | BN13 | BE0190 | BE0085 |
| CXCR3 (CD183) | Mouse | <i>in vivo</i> CXCR3 neutralization, FC | CXCR3-173 | BE0249 | BE0091 |
| Delta-like protein 4 (DLL4) | Mouse | <i>in vivo</i> DLL4 neutralization, <i>, in vitro</i> DLL4 neutralization | HMD4-2 | BE0127 | BE0091 |
| DR5 (CD262) | Mouse | <i>in vivo</i> induction TRAIL-mediated apoptosis, <i>in vitro</i> induction TRAIL-mediated apoptosis | MD5-1 | BE0161 | BE0091 |
| F4/80 | Mouse | <i>in vivo</i> Monocyte/Macrophage depletion, Functional assays, IHC-P, IHC-F, FC | Cl:A3-1 | BE0206 | BE0090 |
| FasL (CD178) | Mouse | <i>in vivo</i> FasL blockade, <i>In vitro</i> FasL blockade, Functional assay, IHC-P, FC | MFL3 | BE0319 | BE0091 |
| FGL-1 | Mouse | <i>in vivo</i> FGL-1 blockade, <i>in vitro</i> FGL-1 blockade, FC, IHC-P | 177R4 | BE0332 | BE0083 |
| Galectin-9 | Mouse | <i>in vivo</i> Galectin-9 blockade <i>in vitro</i> Galectin-9 blockade | RG9-1 | BE0218 | BE0090 |
| GITR | Mouse | <i>in vivo</i> GITR stimulation | DTA-1 | BP0063 | BP0090 |
| GM-CSF | Mouse | <i>in vivo</i> GM-CSF neutralization, <i>in vitro</i> GM-CSF neutralization, FC | MP1-22E9 | BE0259 | BE0089 |
| ICOS | Mouse | <i>in vivo</i> blocking of ICOS/ICOSL signaling, FC | 7E.17G9 | BE0059 | BE0090 |
| ICOSL (CD275) | Mouse | <i>in vivo</i> ICOSL neutralization | HK5.3 | BE0028 | BE0089 |
| IFNAR-1 | Mouse | <i>in vivo</i> IFNAR-1 blockade, <i>in vitro</i> IFNAR-1 blockade, WB | MAR1-5A3 | BP0241 | BP0083 |
| IFN γ | Mouse | <i>in vivo</i> IFN γ neutralization, <i>in vitro</i> IFN γ neutralization | R4-6A2 | BE0054 | BE0088 |
| IFN γ | Mouse | <i>in vivo</i> IFN γ neutralization, <i>in vitro</i> IFN γ neutralization, ELISPOT, FC, WB | XMG1.2 | BP0055 | BP0088 |
| IFN γ | Human | <i>in vivo</i> IFN γ neutralization in humanized mice, <i>, in vitro</i> IFN γ neutralization | B133.5 | BE0235 | BE0083 |
| IFN γ | Human | FC | B27 | BE0245 | BE0083 |



Immunoprecipitation | FC Flow cytometry (requires fluochrome conjugation)

Your Trusted Supplier of *in vivo* MAbs.



| Antigen | Reactivity | Application | Clone | Catalog # | Isotype Control |
|---------------------------------------|--------------|---|----------------|-----------|-----------------|
| IFN γ | Mouse | <i>in vivo</i> IFN γ neutralization, <i>in vitro</i> IFN γ neutralization | H22 | BE0312 | BE0091 |
| IFN γ R (CD119) | Mouse | <i>in vivo</i> IFN γ R neutralization, , <i>in vitro</i> IFN γ R neutralization | GR-20 | BE0029 | BE0089 |
| IFN γ R α (CD119) | Mouse | WB, IP, FC | 2E2 | BE0287 | BE0091 |
| IL-1R (CD121a) | Mouse | <i>in vivo</i> IL-1R blockade, , <i>in vitro</i> IL-1R blockade | JAMA-147 | BE0256 | BE0091 |
| IL-1 α | Mouse | <i>in vivo</i> IL-1 α neutralization, , <i>in vitro</i> IL-1 α neutralization | ALF-161 | BE0243 | BE0091 |
| IL-1 β | Mouse/Rat | <i>in vivo</i> IL-1 β neutralization, <i>in vitro</i> IL-1 β neutralization, ELISA | B122 | BE0246 | BE0091 |
| IL-2 | Mouse | <i>in vivo</i> and <i>in vitro</i> IL-2 neutralization, <i>in vivo</i> IL-2 receptor stimulation (as a complex with IL-2), ELISPOT, FC | JES6-5H4 | BE0042 | BE0090 |
| IL-2 | Mouse | <i>in vivo</i> IL-2 neutralization, <i>in vivo</i> IL-2 receptor stimulation (as a complex with IL-2) | JES6-1A12 | BE0043 | BE0089 |
| IL-2 | Mouse | <i>in vivo</i> IL-2 neutralization, <i>in vivo</i> IL-2 receptor stimulation (as a complex with IL-2) | S4B6-1 | BE0043-1 | BE0089 |
| IL-3 | Mouse | <i>in vivo</i> and <i>in vitro</i> IL-3 neutralization, <i>in vivo</i> IL-3 receptor stimulation (as a complex with IL-3), ELISA, FC | MP2-8F8 | BE0282 | BE0088 |
| IL-4 | Mouse | <i>in vivo</i> and <i>in vitro</i> IL-4 neutralization, <i>in vivo</i> IL-4 receptor stimulation (as a complex with IL-4), FC, WB | 11B11 | BP0045 | BP0088 |
| IL-4 | Mouse | ELISA, ELISPOT, FC | BVD6-24G2 | BE0199 | BE0088 |
| IL-4 | Human | <i>in vitro</i> IL-4 neutralization, FC | MP4-25D2 | BE0240 | BE0088 |
| IL-5 | Mouse/Human | <i>in vivo</i> IL-5 neutralization, <i>in vivo</i> eosinophil depletion | TRFK5 | BE0198 | BE0088 |
| IL-6 | Mouse | <i>in vivo</i> IL-6 neutralization, <i>in vitro</i> IL-6 neutralization | MP5-20F3 | BE0046 | BE0088 |
| IL-6R | Mouse | <i>in vivo</i> blocking of IL-6/IL-6R signaling, <i>in vitro</i> blocking of IL-6R signaling | 15A7 | BE0047 | BE0090 |
| IL-7 | Mouse/Human | <i>in vivo</i> IL-7 neutralization, <i>in vivo</i> IL-7 receptor stimulation (as a complex with IL-7) | M25 | BE0048 | BE0086 |
| IL-7R α (CD127) | Mouse | <i>in vivo</i> blocking of IL-7R α signaling, FC | A7R34 | BE0065 | BE0089 |
| IL-9 | Mouse | <i>in vivo</i> IL-9 neutralization | 9C1 | BE0181 | BE0085 |
| IL-10 | Mouse | <i>in vivo</i> IL-10 neutralization, <i>in vitro</i> IL-10 neutralization | JES5-2A5 | BE0049 | BE0088 |
| IL-10R (CD210) | Mouse | <i>in vivo</i> blocking of IL-10/IL-10R signaling, <i>in vitro</i> blocking of IL-10R signaling, FC, WB | 1B1.3A | BP0050 | BP0088 |
| IL-12 | Mouse | <i>in vivo</i> IL-12 neutralization, , <i>in vitro</i> IL-12 neutralization | R1-5D9 | BE0052 | BE0089 |
| IL-12 p35 | Mouse | <i>in vivo</i> IL-12 p35 neutralization, <i>in vitro</i> IL-12 p35 neutralization, ELISA, IP | C18.2 | BE0371 | BE0089 |
| IL-12 p40 | Mouse | <i>in vivo</i> IL-12p40 neutralization, p40 affinity chromatography, IP, ELISA, FC, WB | C17.8 | BP0051 | BP0089 |
| IL-12 p70 | Human | Functional assays, ELISA, FC | 20C2 | BE0234 | BE0088 |
| IL-12 p75 | Mouse | <i>in vivo</i> IL-12p75 neutralization, ELISA | R2-9A5 | BE0233 | BE0090 |
| IL-15 | Mouse | <i>in vivo</i> IL-15 neutralization, <i>in vitro</i> IL-15 neutralization | A10.3 | BE0315 | BE0089 |
| IL-17A | Mouse | <i>in vivo</i> IL-17A neutralization | 17F3 | BP0173 | BP0083 |
| IL-17F | Mouse | <i>in vivo</i> IL-17F neutralization | MM17F8F5.1A9 | BE0303 | BE0083 |
| IL-18 | Mouse | <i>in vivo</i> IL-18 neutralization, <i>in vitro</i> IL-18 neutralization | YIGIF74-1G7 | BE0237 | BE0089 |
| IL-21R | Mouse | <i>in vivo</i> IL-21R blockade | 4A9 | BE0258 | BE0089 |
| IL-23 (p19) | Mouse | <i>in vivo</i> IL-23p19 neutralization, WB | G23-8 | BE0313 | BE0088 |
| IL-27 p28 | Mouse | <i>in vivo</i> IL-27 p28 neutralization, <i>in vitro</i> IL-27 p28 neutralization, FC | MM27.7B1 | BE0326 | BE0085 |
| Jagged2 | Mouse | <i>in vivo</i> Jagged 2 neutralization | HMJ2-1 | BE0125 | BE0091 |
| Kappa Immunoglobulin Light Chain | Rat | <i>in vivo</i> B cell depletion in combination with anti-CD19 (clone ID3) and anti-CD22 (clone Cy34.1) | MAR 18.5 | BE0122 | BE0085 |
| Kappa Immunoglobulin Light Chain | Mouse | IF | 187.1 (HB58) | BE0176 | BE0088 |
| KLRG-1 | Mouse/Human | FC | 2F1 | BE0201 | BE0087 |
| LAG-3 | Mouse | <i>in vivo</i> LAG-3 neutralization, <i>in vitro</i> LAG-3 neutralization, FC, WB | C9B7W | BP0174 | BP0088 |
| Ly6C | Mouse | <i>in vivo</i> macrophage depletion (in combination with clodronate liposomes), FC | Monts 1 | BE0203 | BE0089 |
| Ly6G | Mouse | <i>in vivo</i> neutrophil depletion, <i>in vivo</i> MDSC depletion, IF, IHC-P, IHC-F, FC | 1A8 | BP0075-1 | BP0089 |
| Ly6G/Ly6C (Gr-1) | Mouse | <i>in vivo</i> neutrophil depletion, IHC-P, IHC-F, IF, FC | NIMP-R14 | BE0320 | BE0090 |
| Ly6G/Ly6C (Gr-1) | Mouse | <i>in vivo</i> depletion of Gr-1+ myeloid cells, FC, IHC-P, IHC-F | RB6-8C5 | BP0075 | BP0090 |
| MDR-1 (CD243) | Human/Monkey | <i>in vivo</i> MDR-1 blocking/depletion in xenogeneic murine, tumor models, <i>in vitro</i> MDR-1 blocking, IHC-P | UIC2 | BE0340 | BE0085 |
| MHC Class I (H-2) | Mouse | ex vivo blocking of MHC I-dependent interactions, IF, FC | M1/42.3.9.8 | BE0077 | BE0089 |
| MHC Class I (H-2Kb) | Mouse | <i>in vivo</i> administration, FC | AF6-88.5.5.3 | BE0121 | BE0085 |
| MHC Class I (H-2Kb) | Mouse | <i>in vivo</i> MHC II blockade, Functional assays, Purification of MHC peptide complexes, FC | Y-3 | BE0172 | BE0086 |
| MHC Class I (H-2Kb) bound to SIINFEKL | Mouse | <i>in vivo</i> blocking of Kb -SIINFEKL, Functional assays, FC | 25-D1.16 | BE0207 | BE0083 |
| MHC Class I (H-2Kd, H-2Dd) | Mouse | <i>in vivo</i> activation of APCs | 34-1-2S | BE0180 | BE0085 |
| MHC Class I (H-2Kd) | Mouse | Purification of MHC peptide complexes, <i>in vivo</i> administration, FC | SF1.10 (HB159) | BE0104 | BE0085 |
| MHC Class I (H-2Kk, H-2Dk) | Mouse | <i>in vivo</i> administration, FC | 15-3-1S (HB13) | BE0158 | BE0085 |
| MHC Class I (HLA-A, HLA-B, HLA-C) | Human | Functional assays | W6/32 | BE0079 | BE0085 |
| MHC class II (HLA-DR) | Human/Monkey | <i>in vitro</i> blocking of MHC class II HLA-DR, HLA class II binding assay, <i>in vitro</i> MHC class II HLA-DR expressing cell negative selection, WB, FC | L243 | BE0306 | BE0085 |
| MHC class II (I-A) | Mouse | <i>in vivo</i> blockade of TCR stimulation, FC | Y-3P | BE0178 | BE0085 |

IF Immunofluorescence | IHC-F Immunohistochemistry (frozen) | IHC-P Immunohistochemistry (paraffin) | WB Western blot | IP

| α -mouse TNF α (BP0058) | α -mouse VISTA (BP0310) | InVivoMab vs. InVivoPlus | | | | | | | | | | | | | | | | | | | | | | | | |
|--|---|--|--|--------------------|---------------------|--------------|--|--|--|--|--|--------------------------------|--|--|-------------------------|----------|----------|---------------------------------------|--|--|-----------------------------|--|--|------------------------------|--|--|
|  |  | <table border="1"> <thead> <tr> <th></th><th>InVivoMab > 95%</th><th>InVivoPlus > 95%</th></tr> </thead> <tbody> <tr> <td>purity level</td><td></td><td></td></tr> <tr> <td>protein aggregates validated at $\leq 5\%$</td><td></td><td></td></tr> <tr> <td>azide and carrier protein free</td><td></td><td></td></tr> <tr> <td>endotoxin concentration</td><td>< 2EU/mg</td><td>< 1EU/mg</td></tr> <tr> <td>validated by immunoblot, FC, or ELISA</td><td></td><td></td></tr> <tr> <td>tested for murine pathogens</td><td></td><td></td></tr> <tr> <td>available in bulk quantities</td><td></td><td></td></tr> </tbody> </table> | | InVivoMab > 95% | InVivoPlus > 95% | purity level | | | protein aggregates validated at $\leq 5\%$ | | | azide and carrier protein free | | | endotoxin concentration | < 2EU/mg | < 1EU/mg | validated by immunoblot, FC, or ELISA | | | tested for murine pathogens | | | available in bulk quantities | | |
| | InVivoMab > 95% | InVivoPlus > 95% | | | | | | | | | | | | | | | | | | | | | | | | |
| purity level | | | | | | | | | | | | | | | | | | | | | | | | | | |
| protein aggregates validated at $\leq 5\%$ | | | | | | | | | | | | | | | | | | | | | | | | | | |
| azide and carrier protein free | | | | | | | | | | | | | | | | | | | | | | | | | | |
| endotoxin concentration | < 2EU/mg | < 1EU/mg | | | | | | | | | | | | | | | | | | | | | | | | |
| validated by immunoblot, FC, or ELISA | | | | | | | | | | | | | | | | | | | | | | | | | | |
| tested for murine pathogens | | | | | | | | | | | | | | | | | | | | | | | | | | |
| available in bulk quantities | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Antigen | Reactivity | Application | Clone | Catalog # | Isotype Control |
|---|--|---|-----------------|-----------|-----------------|
| MHC Class II (I-A/I-E) | Mouse | <i>in vivo</i> MHC II blockade, Functional assays, IF, WB, IP, FC | M5/114 | BE0108 | BE0090 |
| MHC II (I-Ak, I-Ar, I-Af, I-As, I-Ag7) | Mouse | <i>in vitro</i> MHC class II I-A blocking, <i>in vitro</i> MHC class II I-A expressing cell negative selection | 10-3.6.2 | BE0068 | BE0085 |
| MHC Class II (I-Ek/RT1-D) | Mouse/Rat | <i>in vivo</i> blocking of antigen presentation, FC | 14-4-4S (HB32) | BE0167 | BE0085 |
| MHC Class II (β chain) | Mouse | WB | KL277 | BE0140 | N/A |
| NK1.1 | Mouse | <i>in vivo</i> NK cell depletion, FC | PK136 | BP0036 | BP0085 |
| NKG2A/C/E | Mouse | <i>in vivo</i> NKG2A blockade (see description), <i>in vitro</i> NKG2A blockade, IHC-F, FC | 20D5 | BE0321 | BE0089 |
| NKG2AB6 | Mouse | FC | 16A11 | BE0339 | BE0086 |
| NKG2D | Mouse | <i>in vivo</i> NKG2D blockade | HMG2D | BE0111 | BE0091 |
| Nonclassical MHC Class I molecule Qa-1b | Mouse | WB, IF | 4C2.4A7.5H11 | BE0165 | BE0083 |
| Notch4 | Mouse | <i>in vivo</i> Notch4 blocking, <i>in vitro</i> Notch4 stimulation, FC | HMN4-14 | BE0129 | BE0091 |
| OX40 (CD134) | Mouse | <i>in vivo</i> OX40 activation, <i>in vitro</i> OX40 activation, WB | OX-86 | BP0031 | BP0088 |
| OX40L (CD134L) | Mouse | <i>in vivo</i> blocking of OX40/OX40L signaling, <i>in vitro</i> OX40L neutralization | RM134L | BE0033-1 | BE0090 |
| PD-1 (CD279) | Mouse | <i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, WB | J43 | BP0033-2 | BP0091 |
| PD-1 (CD279) | Mouse | <i>in vivo</i> blocking of PD-1/PD-L signaling | RMP1-14 | BP0146 | BP0089 |
| PD-1 (CD279) | Human | <i>in vitro</i> PD-1 neutralization, <i>in vivo</i> PD-1 blockade in humanized mice | J116 | BE0188 | BE0083 |
| PD-1 (CD279) | Human | <i>in vivo</i> PD-1 blockade in humanized mice, FC | J110 | BE0193 | BE0083 |
| PD-1 (CD279) | Mouse | <i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, IF, WB, FC | 29F.1A12 | BP0273 | BP0089 |
| PD-1 (p248Tyr) | Mouse/Human | WB, FC | 407.G12 | BE0387 | BE0085 |
| PD-L1 (B7-H1) | Mouse | <i>in vivo</i> and <i>in vitro</i> blocking of PD-L1/CD80 (B7-1) interactions, ELISA, FC | 10F.2H11 | BE0361 | BE0090 |
| PD-L1 (B7-H1) | Mouse/Human/Rat | <i>in vivo</i> PD-L1 blockade, <i>in vitro</i> PD-L1 blockade, FC | 368A.4H1 | BE0383 | BE0083 |
| PD-L1 (B7-H1) | Mouse | <i>in vivo</i> PD-L1 blockade, IF, IHC-F, FC, WB | 10F.9G2 | BP0101 | BP0090 |
| PD-L1 (B7-H1) | Human | <i>in vitro</i> PD-L1 blockade, Functional assays, IHC-F, FC | 29E.2A3 | BE0285 | BE0086 |
| PD-L2 (B7-DC) | Mouse | <i>in vivo</i> PD-L2 blockade, <i>in vitro</i> PD-L2 blockade, IHC-F, FC | TY25 | BE0112 | BE0089 |
| PSGL-1 (CD162) | Mouse | <i>in vivo</i> PSGL-1 blockade, IHC-F | 4RA10 | BE0186 | BE0088 |
| RANKL (CD254) | Mouse | <i>in vivo</i> RANKL blockade | IK22/5 | BE0191 | BE0089 |
| Siglec-H | Mouse | <i>in vivo</i> administration, FC | 440c | BE0202 | BE0090 |
| TCR V γ 1.1/Cr4 | Mouse | <i>in vivo</i> V γ 1 TCR+ cell depletion, FC | 2.11 | BE0257 | BE0091 |
| TCR γ/δ | Mouse | <i>in vivo</i> TCR γ/δ neutralization, <i>in vitro</i> γ/δ T cell stimulation, <i>in vitro</i> γ/δ T cell purification, Functional assays, IP, FC | UC7-13D5 | BE0070 | BE0091 |
| TCR β | Mouse | <i>in vivo</i> T cell depletion | H57-597 (HB218) | BE0102 | BE0091 |
| Ter-119 | Mouse | <i>in vivo</i> administration, <i>in vitro</i> erythrocyte negative selection, Functional assays, FC | TER-119 | BE0183 | BE0090 |
| TGF- β | Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine | <i>in vivo</i> TGF β neutralization, <i>in vitro</i> TGF β neutralization, WB | 1D11.16.8 | BP0057 | BP0083 |
| Thy1 (CD90) | Mouse | <i>in vitro</i> T cell depletion | M5/49.4.1 | BE0076 | BE0089 |
| Thy1.1 (CD90.1) | Mouse | <i>in vivo</i> T cell depletion | 19E12 | BE0214 | BE0085 |
| Thy1.2 (CD90.2) | Mouse | <i>in vivo</i> ILC depletion, <i>in vivo</i> T cell depletion, WB | 30H12 | BP0066 | BP0090 |
| TIGIT | Mouse | <i>in vivo</i> TIGIT stimulation, FC | 1G9 | BE0274 | BE0083 |
| TIM-1 (CD365) | Mouse | <i>in vivo</i> TIM-1 blockade | RMT1-10 | BE0113 | BE0089 |
| TIM-1 (CD365) | Mouse | <i>in vivo</i> TIM-1 activation, <i>in vitro</i> T cell stimulation/activation, Functional assays, ELISA, FC | 3B3 | BE0289 | BE0089 |
| TIM-1 (CD365) | Mouse | <i>in vivo</i> TIM-1 blockade, <i>in vitro</i> TIM-1 blockade | 3D10 | BE0314 | BE0088 |
| TIM-3 (CD366) | Mouse | <i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC | RMT3-23 | BP0115 | BP0089 |
| TIM-3 (CD366) | Mouse | <i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC | B8.2C12 | BE0275 | BE0088 |
| TIM-4 | Mouse | <i>in vivo</i> TIM-4 blockade, <i>in vitro</i> TIM-4 blockade, IF | RMT4-53 | BE0171 | BE0090 |
| TIM-4 | Mouse | <i>in vitro</i> TIM-4 blocking, IF, FC | RMT 4-54 | BE0225 | BE0089 |
| TL1A (TNFSF15) | Mouse | <i>in vivo</i> TL1A neutralization, FC | 5G4.2 | BE0323 | BE0091 |
| TNFR2 (CD120b) | Mouse | <i>in vivo</i> TNFR2 blockade, <i>in vitro</i> TNFR2 blockade | TR75-54.7 | BE0247 | BE0091 |
| TNF α | Mouse | <i>in vivo</i> TNF α neutralization, <i>in vitro</i> TNF α neutralization, WB | XT3.11 | BP0058 | BP0088 |
| TNF α | Mouse/Rat/Rabbit | <i>in vivo</i> TNF α neutralization, FC | TN3-19.12 | BE0244 | BE0091 |
| VISTA | Mouse | <i>in vivo</i> blocking of VISTA signaling, <i>in vitro</i> blocking of VISTA signaling | 13F3 | BP0310 | BP0091 |
| V β 4 TCR | Mouse | <i>in vivo</i> administration, FC | KT4 | BE0166 | BE0090 |
| V γ 2 TCR | Mouse | <i>in vivo</i> γ/δ T cell depletion, FC | UC3-10A6 | BE0168 | BE0091 |

Immunoprecipitation | FC Flow cytometry (requires fluochrome conjugation)

Your Trusted Supplier of *in vivo* MAbs.



For over 25 years, scientists have trusted Bio X Cell as their go-to source for *in vivo* functional grade antibodies. This is reflected in over 20,000 peer-reviewed publications citing Bio X Cell products. We understand this responsibility is of paramount importance and remain committed to producing antibodies of unparalleled quality and consistency, enabling our partners around the globe to accelerate research and discoveries.



Distributed by



www.2BScientific.com
+44 (0)1869 238 033
sales@2BScientific.com

Products are for Research Use Only – Not for therapeutic or diagnostic purposes